Published in Immunotherapy Weekly, April 24th, 2002
The prospectively randomized, phase II comparative study examined the use of Thymoglobulin or Simulect as induction therapy in high-risk kidney transplants. Induction therapy is administered at the time of transplant to prevent future acute rejection of the transplanted organ. In the U.S., Thymoglobulin is indicated only for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.